Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H (HK:2196)
:2196
Want to see HK:2196 full AI Analyst Report?
2196 Stock Chart & Stats
HK$19.63
-HK$0.04(-0.30%)
At close: 4:00 PM EST
HK$19.63
-HK$0.04(-0.30%)
Day’s Range― - ―
52-Week RangeHK$15.34 - HK$29.00
Previous CloseN/A
Volume1.35M
Average Volume (3M)8.63M
Market Cap
HK$63.41B
Enterprise ValueHK$88.21B
Total Cash (Recent Filing)HK$15.29B
Total Debt (Recent Filing)HK$31.86B
Price to Earnings (P/E)16.6
Beta1.13
Next Earnings
Sep 01, 2026EPS Estimate
0.43Next Dividend Ex-DateN/A
Dividend Yield1.69%
Share Statistics
EPS (TTM)1.30
Shares Outstanding551,940,500
10 Day Avg. Volume5,166,409
30 Day Avg. Volume8,626,817
Financial Highlights & Ratios
PEG Ratio0.74
Price to Book (P/B)0.95
Price to Sales (P/S)1.15
P/FCF Ratio60.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$31.17Price Target Upside58.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)1.48
Revenue Forecast (FY)HK$44.01B
Bulls Say, Bears Say
Bulls Say
Revenue Rebound And Solid MarginsA large TTM revenue rebound alongside near-50% gross margin and positive net margin indicates demand recovery and improved mix or pricing power. This strengthens durable revenue base and margin capacity, supporting investment in R&D and scale benefits over the next several months.
Diversified Healthcare Business ModelIntegrated operations across manufacturing, distribution and medical services create multiple revenue streams and capture margin across the value chain. This vertical diversification reduces single-channel dependency and provides structural resilience to procurement or channel disruptions.
Improved Cash Generation TrendThe return to positive operating cash flow and FCF after prior deficits improves the company’s ability to fund capex, R&D and working capital internally. Sustained cash generation reduces near-term refinancing reliance and supports strategic initiatives over the medium term.
Bears Say
Weak Cash ConversionLow FCF-to-earnings means reported profits are not translating efficiently into cash, implying working-capital or collection pressures. This structural weakness limits reinvestment capacity, raises execution risk, and could strain liquidity if investment needs or receivables increase.
Moderate Leverage And Middling ReturnsA meaningful but manageable debt load combined with only ~7% ROE signals moderate capital efficiency. Debt servicing and limited return on equity constrain capacity for large expansion or M&A without raising leverage, and may cap shareholder return upside over time.
Moderate And Pressured Operating MarginsSubdued and declining operating margins point to cost pressure or adverse product mix. Persistent margin compression would limit free cash flow improvement and the company’s ability to invest in higher-margin innovation, making earnings gains more fragile over time.
Shanghai Fosun Pharmaceutical (Group) Co News
2196 FAQ
What was Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price range in the past 12 months?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H lowest stock price was HK$15.34 and its highest was HK$29.00 in the past 12 months.
What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap is HK$63.41B.
When is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date is Sep 01, 2026 which is in 87 days.
How were Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s earnings last quarter?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H released its earnings results on Apr 28, 2026. The company reported HK$0.38 earnings per share for the quarter, beating the consensus estimate of HK$0.374 by HK$0.006.
Is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H overvalued?
According to Wall Street analysts Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price is currently Undervalued.
Does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pay dividends?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pays a Annually dividend of HK$0.35 which represents an annual dividend yield of 1.69%. See more information on Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H dividends here
What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate is 0.43.
How many shares outstanding does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H have?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H has 551,940,500 shares outstanding.
What happened to Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price movement after its last earnings report?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H reported an EPS of HK$0.38 in its last earnings report, beating expectations of HK$0.374. Following the earnings report the stock price went up 1.268%.
Which hedge fund is a major shareholder of Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H?
Currently, no hedge funds are holding shares in HK:2196
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Fosun Pharmaceutical (Group) Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$31.17 (58.81% Upside)
HK$31.17 (58.81% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.70%
12-Months-Change
Fundamentals
Return on Equity
7.19%
Trailing 12-Months
Asset Growth
9.40%
Trailing 12-Months
Company Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments. The company offers pharmaceutical products in the areas of tumor, immune modulation, metabolism, alimentary and central nervous system. It also provides medical devices and diagnostic products. In addition, the company offers health care and hospital management services. Further, it engages in retail and wholesale distribution of medicines. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
2196 Stock 12 Month Forecast
Average Price Target
HK$31.17
▲(58.81% Upside)
Technical Analysis
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Hansoh Pharmaceutical Group Company Limited
―
Options Prices
Currently, No data available
---